Infection treatment biotech Ruthigen files for a $27 million IPO
Ruthigen, a biotech developing therapeutics to prevent and treat infection in surgical and trauma procedures, filed on Thursday with the SEC to raise up to $27 million in an initial public offering. The Santa Rosa, CA-based company, which was founded in 2013, plans to list on the NASDAQ under the symbol RTGN. Ruthigen initially filed confidentially on May 24, 2013. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.